國藥科技股份(08156.HK)首批防偽產品正式交付
格隆匯11月10日丨國藥科技股份(08156.HK)發佈公吿,截至該公吿日首批國科防偽創新型防偽產品在甘肅省正式完成交付予茶葉行業企業用户,標誌着集團的防偽產品正式在市場上應用而集團將開始在此業務分部中產生收入,實現防偽業務重要的里程碑。至此,集團防偽業務由銷售、生產至交付全流程完整打通。
集團於甘肅省完成從首個防偽業務商業合同的簽訂至今達成首批交付,對於集團開啟防偽業務的新篇章具有重大意義。此外,集團此次於甘肅省的交付,配合農特產品的應用場景,企業用户與集團共同加強隴南市地理標誌農產品保護,為品牌升級發展提供扶持,助力鄉村振興。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.